GET DAILY SIGNALSRecursion Pharmaceuticals (RXRX) Q3 2026 Results Highlight Narrower Losses and Extended Cash Runway
Key Takeaways
- Recursion reported third-quarter 2026 revenue of $18.6 million, up from $5.2 million a year earlier, driven by a $10 million milestone payment from its Sanofi collaboration.
- Net loss narrowed to $119.0 million from $162.3 million in the prior-year quarter, helped by lower research and development (R&D) and general and administrative (G&A) spending.
- The loss per share of $0.22 came in narrower than the consensus estimate of a $0.24 loss, while revenue exceeded expectations.
- Pro forma cash of roughly $748.7 million, including an October follow-on offering, supports a runway that now extends into 2029.
- Updated clinical data for REC-4881 and REC-1245, plus a new Sanofi option exercise, reinforced the company's pipeline momentum.
- Management reiterated full-year 2026 cash operating expense guidance of less than $375 million and set 2027 guidance below $360 million.
Earnings Context and Why It Matters
As a clinical-stage, AI-enabled drug discovery company with no approved products yet, Recursion's quarterly reports are watched less for traditional revenue and more for three things: cost discipline, cash runway, and clinical or partnership milestones that validate its platform. This report delivered on all three fronts. The top line was lifted by a lumpy but meaningful collaboration milestone from Sanofi, while tighter spending and a fresh capital raise extended the company's runway further into the future. From what I see, the bigger story sits in the updated data for REC-4881 and REC-1245 and the continued willingness of large pharmaceutical partners to option its AI-generated drug candidates, which together shape confidence in Recursion's core promise of turning machine-driven discovery into medicines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Recursion reported total revenue of $18.6 million for the third quarter of 2026, up from $5.2 million in the same period a year earlier. The increase was driven primarily by a $10.0 million milestone payment from Sanofi, which exercised an option on the first development candidate from the companies' collaboration. Net loss narrowed to $119.0 million from $162.3 million in the prior-year quarter, while the net loss per share of $0.22 came in narrower than the consensus estimate of a $0.24 loss. R&D expenses fell to $99.1 million from $121.1 million, partly reflecting prior-year in-process R&D costs that did not recur, and G&A expenses declined to $32.6 million from $41.6 million.
On the balance sheet, cash, cash equivalents, and restricted cash totaled $561.5 million as of September 30, 2026. Including roughly $187.2 million in net proceeds from an October 2026 follow-on offering, pro forma cash was approximately $748.7 million, which management said extends the company's cash runway into 2029. Recursion reiterated full-year 2026 cash operating expense guidance of less than $375 million and set 2027 guidance below $360 million.
Market Reaction and Investor Sentiment
The earnings beat was a welcome signal for RXRX, which has been under pressure this year, with shares down modestly in 2026 against broader industry gains. The market's focus, however, appeared to center less on the headline revenue beat—which was heavily dependent on a single milestone payment—and more on the combination of a longer cash runway, disciplined spending, and incremental clinical de-risking. Updated REC-4881 data showing polyp burden reductions in familial adenomatous polyposis (FAP), a hereditary condition that causes numerous precancerous polyps, and the first efficacy signals from REC-1245 gave investors concrete clinical validation rather than platform promises alone. Still, sentiment remains tempered by the early-stage nature of the datasets and by the dilutive follow-on offering that helped fund the extended runway.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch several catalysts tied to the pipeline rather than the income statement. Recursion said it anticipates initiating a registrational trial for REC-4881 in the second half of 2027, pending discussions with the U.S. Food and Drug Administration (FDA). The design and timing of that study, given limited regulatory precedent in FAP, will be a key swing factor for the stock.
For REC-1245, an oral degrader targeting a protein called RBM39 (a splicing factor involved in DNA repair), preliminary dose-expansion data in endometrial cancer are expected in the second half of 2027. Because the current efficacy signal rests on a small patient group, investors will watch whether responses hold up as enrollment broadens.
Partnership economics also matter. Sanofi's option of the first development candidate triggered a $10 million milestone and brought total payments under that collaboration to $144 million, with more than $300 million in additional milestones potentially available. Roche's Genentech separately advanced its first validated neuroscience target. Continued milestone flow from these alliances would support the company's funding position without requiring further equity raises.
Finally, spending discipline remains central to the story. With 2027 cash operating expense guidance below $360 million and a runway into 2029, execution on cost controls will determine how much financial flexibility Recursion retains as it advances multiple clinical programs toward later-stage trials. I’m watching this closely for signs of continued momentum.
Using Tickeron AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener have become a practical part of my routine when reviewing clinical-stage names such as RXRX. It helps me quickly filter for comparable companies based on technical patterns, fundamentals, and AI-driven signals without spending hours on manual work. This kind of efficiency lets me focus more on the underlying pipeline catalysts rather than getting lost in raw data. For anyone following similar biotech stories, it offers a straightforward way to surface additional context and ideas that align with your own research criteria.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for RXRX turns positive, indicating new upward trend
RXRX saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 85 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 112 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 57 cases where RXRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
RXRX moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (3.051). P/E Ratio (-3.880) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement